Search Results

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology Annual Meeting 2024.

Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.

Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the total contract award to de